These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 16721122

  • 1. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
    de Castro G, Awada A.
    Curr Opin Oncol; 2006 Jul; 18(4):307-15. PubMed ID: 16721122
    [Abstract] [Full Text] [Related]

  • 2. Review: side effects of approved molecular targeted therapies in solid cancers.
    Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A.
    Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
    [Abstract] [Full Text] [Related]

  • 3. Targeted therapies: a nursing perspective.
    Kay P.
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [Abstract] [Full Text] [Related]

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 5. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T, Gridelli C, Ciardiello F.
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, Delattre JY.
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA.
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [Abstract] [Full Text] [Related]

  • 8. Targeted therapies: a new generation of cancer treatments.
    Gerber DE.
    Am Fam Physician; 2008 Feb 01; 77(3):311-9. PubMed ID: 18297955
    [Abstract] [Full Text] [Related]

  • 9. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S, Schiller JH.
    Crit Rev Oncol Hematol; 2007 May 01; 62(2):93-104. PubMed ID: 17306557
    [Abstract] [Full Text] [Related]

  • 10. Molecular targeted therapies for solid tumors: management of side effects.
    Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.
    Onkologie; 2009 Mar 01; 32(3):129-38. PubMed ID: 19295254
    [Abstract] [Full Text] [Related]

  • 11. Novel therapies in myeloma.
    Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.
    Curr Opin Hematol; 2007 Nov 01; 14(6):609-15. PubMed ID: 17898564
    [Abstract] [Full Text] [Related]

  • 12. The persisting challenge of selective and specific proteasome inhibition.
    Groll M, Huber R, Moroder L.
    J Pept Sci; 2009 Feb 01; 15(2):58-66. PubMed ID: 19109822
    [Abstract] [Full Text] [Related]

  • 13. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Nov 01; 115(2):215-20. PubMed ID: 19712963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD, Moehler M.
    Curr Opin Oncol; 2009 Jul 01; 21(4):381-5. PubMed ID: 19412098
    [Abstract] [Full Text] [Related]

  • 16. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K.
    Rinsho Ketsueki; 2007 Jun 01; 48(6):451-7. PubMed ID: 17633092
    [No Abstract] [Full Text] [Related]

  • 17. New agents in development for breast cancer.
    Gao XP, Liu F.
    Curr Opin Obstet Gynecol; 2007 Feb 01; 19(1):68-74. PubMed ID: 17218855
    [Abstract] [Full Text] [Related]

  • 18. New drugs for myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.
    Oncologist; 2007 Jun 01; 12(6):664-89. PubMed ID: 17602058
    [Abstract] [Full Text] [Related]

  • 19. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C, Vidal L, Siu LL.
    Drug Resist Updat; 2008 Jun 01; 11(3):99-109. PubMed ID: 18515176
    [Abstract] [Full Text] [Related]

  • 20. [Molecular-targeted therapy for malignant glioma].
    Yamanaka R.
    Brain Nerve; 2009 Feb 01; 61(2):177-88. PubMed ID: 19235468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.